Adalimumab Biosimilars Demonstrate Long-Term Durability and Cost-Effectiveness in Paediatric Inflammatory Bowel Disease: A Real-World Two-Centre European Cohort Study

Adalimumab Biosimilars Demonstrate Long-Term Durability and Cost-Effectiveness in Paediatric Inflammatory Bowel Disease: A Real-World Two-Centre European Cohort Study

Silvana Ancona,1,2 Katherine Armstrong,2 Chiara Longo,3 Rosalind Rabone,2 Victoria Merrick,2 Paul Henderson,2,4 Paolo Gandullia,3 David C Wilson,2,4 Serena Arrigo,3 Richard K Russell2,4 1Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Gen...

Full description

Saved in:
Bibliographic Details
Main Authors: Ancona S, Armstrong K, Longo C, Rabone R, Merrick V, Henderson P, Gandullia P, Wilson DC, Arrigo S, Russell RK
Format: Article
Language:English
Published: Dove Medical Press 2025-04-01
Series:Biologics: Targets & Therapy
Subjects:
biosimilar
adalimumab
paediatric inflammatory bowel disease.
Online Access:https://www.dovepress.com/adalimumab-biosimilars-demonstrate-long-term-durability-and-cost-effec-peer-reviewed-fulltext-article-BTT
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items